title: Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone.
abstract: The prognostic effect of pretreatment patient- and tumor characteristics, and the influence of radiotherapy schedule on local control, distant metastases, and crude survival were analyzed in 424 consecutive patients with FIGO stage IIB (n = 137), IIIA (n = 10), IIIB (n = 211) and IVA (n = 66) cancer of the uterine cervix. All patients were given radiotherapy alone. From 1974 and through 1977, the external and intracavitary combined radiotherapy was given continuously in 4 to 6 weeks. From 1978 and through 1983, the treatment policy was changed to split-course radiotherapy by introducing planned pauses, resulting in an overall treatment time of 10 to 12 weeks. The results were estimated by univariate actuarial- and Cox multivariate regression analyses. Multivariate analysis showed that significant adverse variables for local control were large lateral tumor diameter, young age, low hemoglobin at time of admission, many pregnancies, split-course strategy, and high FIGO stage. Risk of metastases increased with decreasing hemoglobin, increasing malignancy grade and split-course treatment. Poor survival probability were related to large lateral tumor diameter, high malignancy grade and FIGO stage, low hemoglobin, split-course therapy, and adeno/adenosquamous tumor type.
authors.affiliation: Department of Oncology, Aarhus University Hospital, Denmark.
authors.forename: D
authors.initials: D
authors.lastname: Pedersen
authors.forename: H
authors.initials: H
authors.lastname: Søgaard
authors.forename: J
authors.initials: J
authors.lastname: Overgaard
authors.forename: S M
authors.initials: SM
authors.lastname: Bentzen
mesh_terms: D000206:Actuarial Analysis; D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002277:Carcinoma / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D018196:Carcinoma, Adenosquamous / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011247:Pregnancy; D011379:Prognosis; D011879:Radiotherapy Dosage; D012044:Regression Analysis; D012074:Remission Induction; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D006454:Hemoglobins